DexCom Inc. (DXCM) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

$79.93 +1.67% NASDAQ • Public Delayed / 60s Snapshot

DexCom Inc. (DXCM) earns a Roarable Rating of B (Buy) with 73/100 RQD Confidence. High-quality cash engine (60% profit margin, 22% return on capital) with steady institutional support. Even if the broader market gets choppy, the company’s underlying cash engine and big-money support put the odds in buyers’ favor.

ROARABLE B • BUY Cap $30.16B

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERBUY • B

2-of-3 JEV AI Jury Bullish

Cash

SEC

Whale

5-PILLAR SNOWFLAKE RADARRw C+ · Rk B+

Each axis scored 0–20

12M PRICE TARGET CONE+6.8% Base Target

WHALE OPTIONS TUG-OF-WAR:54% Call Buyers ($2.9M)

46% PutsMax Pain: $78.00

SEC FORM 4 × 13F HEDGE FUNDS × CONGRESSIONAL STOCK ACT

DXCM Smart-Money Thermometer: BALANCED INSTITUTIONAL POSITIONING

Explore All 13F & Congress Whales →

▲ Disclosed Buys: 0 ($0)▼ Disclosed Sales: 0 ($0)

Wide-Open SEC Form 4, 13F & Congressional Disclosure Ledger (DXCM)

No recent open-market Form 4 cluster sales or emergency dumps flagged on DXCM. Visit the Global 13F & Congressional Whale Ledger for cross-market smart-money filings.

🔴 SUNDAY NIGHT PREP • 7:00 PM ETHosted Live by Perry Belcher & Guest Trading Systems Desk

Today's Top 3 RQD Strong Buys & Whale Accumulation Setups (Live DXCM Tape Review)

✓Live breakdown of today’s highest-scoring RQD Green-Light breakouts
✓1 urgent Red-Light accounting trap to cut from your watchlist immediately
✓Bring any ticker to live Q&A—we run it through the 5-Pillar RQD Radar on screen

RQD INSIDER CLUB UPGRADE$49/YEAR

Want Plain-English AI Custom Indicators, Daily Pro Trader Video Clips & SMS Crash Alerts?

🤖 Try AI Indicator Builder ($49/yr VIP) →$100K Arena

DXCM // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +38.19%📐 WEDGE COMPRESSION COIL

2026-10-30O $81.52H $85.25L $79.79C $82.29VOL 8.64M

RES: $87.89SUP: $76.97SMA50: $85.82SMA200: $74.56

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

DXCM Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 DXCM Butterfly Map → + Track DXCM →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

27.8%/yr Implied 5Y Growth

vs. +15.6% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on DXCM today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

LLY → DXCM Analyst Hypothesis

Real-world payer claims data show clinicians co-prescribe Dexcom G7 and OTC Stelo continuous glucose monitors (CGMs) alongside GLP-1 initiation for metabolic feedback, offsetting delayed progression to basal insulin.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for DXCM today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DXCM Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Are DXCM insiders and hedge funds buying or selling?

Roarable's SEC Form 4 and 13F Whale Thermometer currently classifies DXCM leadership and institutional positioning as: BALANCED INSTITUTIONAL POSITIONING.

Direct Sub-Reports: DXCM RQD Cockpit DXCM 12M Forecast DXCM Earnings & Move DXCM Dividends & DRIP DXCM Insiders & 13F DXCM Whale Options DXCM Profit Sankey DXCM News & Why